Axsome Therapeutics, Inc.

AXSM Healthcare Biotechnology

Axsome Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $638.5 million, up 65.5% from fiscal 2024.

Revenue
+51.9%
EPS
+73.9%
Free cash flow
−1,078.3%
Total debt
+4.04%

Quarter to September 2026, against a year earlier

132.13 2.33 +1.80%
Market cap
$6.8B
P/E
0.0×
Fwd P/E
−49.2×
Dividend yield
—
F-score
5/9
Altman Z
6.91
Beneish M
−2.53
Dividend safety
n/a

Axsome Therapeutics, Inc. (AXSM) P/E ratio

Alert me on P/E ratio

Axsome Therapeutics, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 0.0× (November 2026) — the current reading is the highest in ten years.

P/E ratio, daily

Embed this chart

Annual newest first

Period P/E ratio Change
FY2025 0.0× —
FY2024 0.0× —
FY2023 0.0× —
FY2022 0.0× —

Quarterly newest first

Period P/E ratio Change
Sep 2026 0.0× —
Jun 2026 0.0× —
Mar 2026 0.0× —
Dec 2025 0.0× —
14 more quarters

Against its own ten years

Low 0.0× High 0.0×
Ten-year median 0.0×
Current reading's percentile 100

P/E ratio against peers

What P/E ratio is

Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.

Stock Price ÷ EPS (Basic) (TTM)

The full definition of P/E ratio →

More on AXSM